Abnormal ECG in Ovarian Cancer: Should You Be Concerned?

An abnormal ECG (electrocardiogram) during ovarian cancer care can have several causes, and it’s often not a sign of immediate danger. Many ECG changes during chemotherapy are mild, transient, and do not require treatment, especially with drugs like paclitaxel that are commonly used in ovarian cancer. ^[1] In clinical data, about 23% of patients had ECG abnormalities during treatment, and most did not have symptoms or need dose changes. ^[2]

---

Why ECG changes happen in cancer care

• Chemotherapy effects (especially paclitaxel): ECG changes such as non‑specific repolarization changes, sinus bradycardia (slow heart rate), sinus tachycardia (fast heart rate), or extra beats can occur during treatment and are usually temporary. ^[2] Among those who started with a normal ECG, roughly 14% developed an abnormal tracing while on therapy. ^[1]
• Arrhythmias and QT changes: Some anti‑cancer medicines can slow the heart, affect conduction, or prolong the QT interval (a measure of electrical recovery), which increases the risk of certain arrhythmias in susceptible people. ^[3] Bradycardia and heart block are among the most frequent, though usually asymptomatic, effects with microtubule agents like paclitaxel. ^[4]
• Underlying risk factors: Pre‑existing heart disease, older age, electrolyte imbalances (low potassium or magnesium), and other medications that prolong QT can make ECG changes more likely. ^[5] Correcting low potassium or magnesium helps reduce rhythm risks and QT prolongation. ^[6]

---

What “abnormal” might mean on an ECG

• Non‑specific repolarization abnormalities: Subtle ST‑T changes that can occur without symptoms; commonly reported and often not clinically significant during therapy. ^[2]
• Sinus bradycardia/tachycardia or premature beats: Rhythm changes that are frequently transient and asymptomatic with paclitaxel. ^[2] In small studies, transient asymptomatic bradycardia occurred in a notable proportion and typically did not require intervention. ^[4]
• QTc prolongation: A lengthening of the QT interval that, if marked, can predispose to dangerous rhythms; monitoring and electrolyte correction are standard. ^[3] If QTc exceeds certain thresholds, clinicians may interrupt or adjust treatment until it normalizes. ^[7]

---

How clinicians usually monitor and manage this

• Baseline and periodic ECGs: Many oncology protocols include an ECG at baseline and then as clinically indicated, particularly when using agents known for cardiac effects. ^[8] Electrolytes (potassium, magnesium, calcium) are typically checked and corrected early in treatment. ^[9]
• Action thresholds for QTc: If the corrected QT (QTc) rises above 480–500 ms, treatment may be paused and resumed at a lower dose once it improves, especially if symptoms or high‑risk rhythms occur. ^[10] Persistent or severe QTc prolongation with dangerous rhythms leads to discontinuation of the offending drug. ^[7]
• Cardiac risk assessment: Before starting potentially cardiotoxic therapy, clinicians often assess cardiovascular risk factors and consider an echocardiogram to evaluate heart function, especially in higher‑risk individuals. ^[11] Ongoing monitoring strategies can be tailored based on whether treatment intent is curative and on patient‑specific risks. ^[12]

---

When to seek urgent care

• Chest pain, shortness of breath, fainting, palpitations, or new severe dizziness during or after infusion should be promptly assessed, as these can signal ischemia or significant arrhythmias. ^[13] Serious cardiac events are less common but can occur, so new symptoms deserve immediate attention. ^[14]

---

Practical tips for you

• Keep your team informed: Report any new heart symptoms promptly so your clinicians can check an ECG and electrolytes and adjust treatment if needed. ^[8] Many ECG changes are monitored without stopping therapy, but timely communication helps keep treatment safe. ^[1]
• Review your medications: Some non‑cancer drugs and supplements can prolong QT; your care team may adjust them during chemotherapy. ^[3] Maintaining normal potassium and magnesium levels reduces rhythm risks. ^[6]
• Know that mild abnormalities are common: In paclitaxel‑treated patients, most ECG changes did not produce symptoms and did not limit dosing. ^[15] This pattern suggests many abnormalities are manageable and not an immediate threat. ^[16]

---

Summary

Abnormal ECGs in ovarian cancer care especially with agents like paclitaxel are relatively common and often mild. Most changes are transient, asymptomatic, and managed with monitoring rather than stopping treatment. ^[1] Your oncology team will typically use baseline and follow‑up ECGs, check electrolytes, and follow clear thresholds to ensure safety. ^[8] If you develop symptoms like chest pain, fainting, or sustained palpitations, seek urgent assessment. ^[13]